Conway E M, Nowakowski B, Steiner-Mosonyi M
Department of Medicine, Toronto Hospital, University of Toronto, Ontario, Canada.
Blood. 1992 Sep 1;80(5):1254-63.
Thrombomodulin (TM) is a surface glycoprotein that forms a 1:1 complex with thrombin, thereby interacting to form the basis of a major physiologically relevant natural anticoagulant mechanism. Although initially described as a vascular endothelial cell receptor, TM has been reported to be present in several other cells, including megakaryocytes, platelets, monocytes, and several cultured cells. Other investigators have reported that neutrophils (PMN) may play a role in the hemostatic mechanism by supporting transformation of prothrombin to thrombin. To determine whether PMN might contribute further to the regulation of the coagulation system, we have evaluated these cells for the expression of TM. Large numbers of human leukocytes were isolated by standard techniques, and the PMN fraction was extracted and shown to be free of platelets and monocytes. Membrane preparations were affinity purified on an anti-TM-Affigel-10 matrix and the eluted material was examined by Western blotting, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and silver staining. The purified material was identical in apparent molecular weight to TM from human placenta and human umbilical vein endothelial cells (HUVEC). Using a sensitive and specific immunoassay, we estimated that there are a minimum of 5,220 +/- 1,658 molecules of TM per PMN, as compared with more than 50,000 in HUVEC. Northern analysis of RNA from PMN indicates that specific messenger RNA for TM, as identified by a single 3.8-kb band, is identical to that from HUVEC, and thereby confirms that PMN can also synthesize the receptor. Localization of TM in PMN was attempted by immunofluorescence, and the receptor was visualized only in permeabilized PMN, but was not seen on the surface of nonpermeabilized cells. Flow cytometry was also used, and could detect TM in 10% to 15% of nonpermeabilized PMN, whereas the antigen was present in greater than 80% of permeabilized cells. Biologic function of the PMN-derived TM, as tested by thrombin-dependent activation of protein C, was absent. Our results suggest that TM is synthesized by PMN, but under nonstimulated conditions, the protein is largely excluded from the membrane surface, and lacks the ability to promote activation of protein C by thrombin. TM from PMN may provide a further link between inflammation and thrombosis and may also be a significant source of plasma TM.
血栓调节蛋白(TM)是一种表面糖蛋白,它与凝血酶形成1:1复合物,从而相互作用形成一种主要的生理相关天然抗凝机制的基础。尽管最初被描述为血管内皮细胞受体,但据报道TM也存在于其他几种细胞中,包括巨核细胞、血小板、单核细胞和几种培养细胞。其他研究人员报告说,中性粒细胞(PMN)可能通过支持凝血酶原向凝血酶的转化而在止血机制中发挥作用。为了确定PMN是否可能进一步参与凝血系统的调节,我们评估了这些细胞中TM的表达情况。通过标准技术分离出大量人类白细胞,提取PMN部分并证明其不含血小板和单核细胞。膜制剂在抗TM-Affigel-10基质上进行亲和纯化,洗脱物通过蛋白质印迹法、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和银染进行检测。纯化后的物质在表观分子量上与人胎盘和人脐静脉内皮细胞(HUVEC)的TM相同。使用灵敏且特异的免疫测定法,我们估计每个PMN中至少有5220±1658个TM分子,而HUVEC中则超过50000个。对PMN的RNA进行Northern分析表明,由一条单一的3.8 kb条带鉴定出的TM特异性信使RNA与HUVEC的相同,从而证实PMN也能合成该受体。通过免疫荧光法尝试对PMN中的TM进行定位,仅在通透的PMN中观察到该受体,而在未通透的细胞表面未见到。还使用了流式细胞术,在10%至15%的未通透PMN中可检测到TM,而在超过80%的通透细胞中存在该抗原。通过凝血酶依赖性蛋白C激活试验检测,PMN来源的TM缺乏生物学功能。我们的结果表明,TM由PMN合成,但在未受刺激的条件下,该蛋白在很大程度上被排除在膜表面之外,并且缺乏促进凝血酶激活蛋白C的能力。PMN来源的TM可能在炎症和血栓形成之间提供进一步的联系,也可能是血浆TM的重要来源。